Studying at the University of Verona

Here you can find information on the organisational aspects of the Programme, lecture timetables, learning activities and useful contact details for your time at the University, from enrolment to graduation.

Study Plan

A.A. 2024/2025 A.A. 2023/2024

This information is intended exclusively for students already enrolled in this course.
If you are a new student interested in enrolling, you can find information about the course of study on the course page:

Laurea magistrale in Biology for Translational Research and Precision Medicine - Enrollment from 2025/2026

The Study Plan includes all modules, teaching and learning activities that each student will need to undertake during their time at the University.
Please select your Study Plan based on your enrollment year.

Legend | Type of training activity (TTA)

TAF (Type of Educational Activity) All courses and activities are classified into different types of educational activities, indicated by a letter.

A Basic activities
B Characterizing activities
C Related or complementary activities
D Activities to be chosen by the student
E Final examination
F Other training activities
S Placements in companies, public or private institutions and professional associations

Terapia cellulare e genica - CELL THERAPIES  (2023/2024)

Teaching code

4S011586

Teacher

Carlo Visco

Credits

3

Language

English en

Scientific Disciplinary Sector (SSD)

MED/15 - BLOOD DISEASES

Period

2 SEMESTRE LM-6 dal Apr 2, 2024 al Jun 21, 2024.

Courses Single

Not Authorized

Lessons timetable MoodleMoodle Seminars 0

To show the organization of the course that includes this module, follow this link:  Course organization

Program

Students will learn on the issues related to stem cells, i.e. those cells that have the unique ability to self-renew and differentiate into a vast range of more specialized cells. Furthermore, the therapies based on engineered lymphocytes, which were initially developed for the treatment of haematological malignancies, will be explored. The first cell therapy approved in Italy by AIFA in August 2019 was the one with CAR-T called tisagenlecleucel, indicated for patients with B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma, which can now be prescribed, with other similar compounds, at the Centers specialists selected by the Regions.

Bibliography

Vai alla bibliografia
Visualizza la bibliografia con Leganto, strumento che il Sistema Bibliotecario mette a disposizione per recuperare i testi in programma d'esame in modo semplice e innovativo.

Didactic methods

Frontal lessons

Learning assessment procedures

Oral exam

Students with disabilities or specific learning disorders (SLD), who intend to request the adaptation of the exam, must follow the instructions given HERE

Evaluation criteria

Vote

Exam language

English